Register Now
Course Information

Join us at A Brave New World: The Clinical Management of Bone Marrow Failure and Myeloid Malignancy in a Time of Personalized Therapy

The complimentary symposium will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The program will bring leaders in disease research and clinical practice together to explore solutions to improve the care of patients.

By attending, you will be able to:

  • Define the clinical implications of aberrant somatic and germline mutations in normal bone marrow, ICUS (idiopathic cytopenias of undetermined significance), CHIP (clonal hematopoiesis of indeterminate potential), myelodysplastic syndrome (MDS), and other myeloid neoplasms
  • Identify the role of targeted therapies in myeloid malignancies
  • Describe the impact of checkpoint inhibitors for the treatment of MDS/AML
  • Describe the treatment options for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PNH)
  • Identify the risks and benefits of bone marrow transplant in therapy-related myeloid malignancies
  • Describe the genomic mutations in MPNs and their impact on pathogenesis and treatment options

Who Should Attend?

The satellite symposium is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

This is a Satellite Symposium organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation, preceding the 59th ASH Annual Meeting.